This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
stem cell | 1831 |
cell transplantation | 1234 |
bone marrow | 931 |
mg kg | 747 |
peripheral blood | 740 |
median age | 623 |
hematopoietic stem | 608 |
extracellular vesicles | 584 |
summary conclusion | 561 |
patients received | 547 |
stem cells | 528 |
overall survival | 524 |
conditioning regimen | 511 |
cd cells | 472 |
chronic gvhd | 464 |
acute gvhd | 463 |
host disease | 452 |
one patient | 424 |
median time | 378 |
median follow | 375 |
nervous system | 374 |
brain injury | 357 |
cerebrospinal fluid | 345 |
spinal cord | 336 |
flow cytometry | 329 |
allogeneic hematopoietic | 309 |
gvhd prophylaxis | 305 |
multiple sclerosis | 303 |
high risk | 298 |
free survival | 296 |
risk factors | 293 |
cd cd | 291 |
two patients | 283 |
central nervous | 265 |
nk cells | 256 |
complete remission | 250 |
allogeneic stem | 250 |
ng ml | 250 |
significantly higher | 244 |
immune response | 243 |
cord blood | 241 |
care unit | 241 |
blood stem | 240 |
stimulating factor | 240 |
cell lines | 224 |
unrelated donor | 221 |
subarachnoid hemorrhage | 220 |
multiple myeloma | 219 |
pg ml | 216 |
neurocritical care | 216 |
allogeneic hsct | 212 |
statistically significant | 210 |
intensive care | 210 |
graft versus | 209 |
patients undergoing | 208 |
patients receiving | 207 |
mean age | 204 |
cmv reactivation | 195 |
control group | 194 |
two groups | 193 |
graft failure | 193 |
autologous stem | 192 |
versus host | 191 |
traumatic brain | 189 |
ischemic stroke | 186 |
status epilepticus | 186 |
cumulative incidence | 183 |
mg dl | 182 |
myeloablative conditioning | 181 |
myeloid cells | 181 |
significant difference | 181 |
cd cell | 180 |
endothelial cells | 178 |
high dose | 176 |
retrospective study | 176 |
multivariate analysis | 175 |
patients treated | 173 |
blood pressure | 173 |
kg day | 171 |
septic shock | 170 |
white matter | 170 |
clinical trials | 170 |
inflammatory response | 169 |
cell count | 168 |
mechanical ventilation | 167 |
myeloid leukemia | 167 |
acute myeloid | 165 |
acute respiratory | 164 |
patients admitted | 163 |
side effects | 161 |
three patients | 160 |
adult patients | 159 |
related mortality | 158 |
ms patients | 158 |
cell transplant | 157 |
grade ii | 156 |
electron microscopy | 156 |
university hospital | 155 |
clinical signs | 155 |
donor chimerism | 154 |
reduced intensity | 153 |
mononuclear cells | 152 |
growth factor | 152 |
data suggest | 150 |
conditioning regimens | 150 |
patients died | 148 |
marrow transplantation | 147 |
five patients | 146 |
within hours | 146 |
derived evs | 146 |
bacterial meningitis | 145 |
four patients | 145 |
case report | 145 |
poor outcome | 144 |
may also | 144 |
patients without | 144 |
intensity conditioning | 143 |
consecutive patients | 142 |
dendritic cells | 142 |
matched unrelated | 142 |
nanoparticle tracking | 140 |
respiratory failure | 139 |
cardiac arrest | 138 |
adverse events | 138 |
grade iii | 137 |
tracking analysis | 136 |
clinical trial | 135 |
patients developed | 134 |
logistic regression | 134 |
virus infection | 133 |
significant differences | 133 |
years old | 132 |
intracranial pressure | 132 |
critically ill | 130 |
immune reconstitution | 129 |
cancer cells | 128 |
western blot | 128 |
acute graft | 127 |
necrosis factor | 127 |
long term | 127 |
relapse mortality | 126 |
organ failure | 126 |
disease progression | 125 |
days post | 125 |
cell source | 124 |
breast cancer | 124 |
unrelated donors | 124 |
increased risk | 123 |
acute leukemia | 123 |
dose chemotherapy | 122 |
gene expression | 122 |
severe acute | 121 |
blood samples | 120 |
cell lymphoma | 120 |
hematopoietic cell | 119 |
significantly associated | 119 |
pediatric patients | 118 |
cell line | 118 |
ex vivo | 118 |
risk factor | 117 |
blood flow | 116 |
growth factors | 116 |
cell types | 115 |
median number | 115 |
lung injury | 114 |
immune system | 113 |
magnetic resonance | 113 |
months post | 112 |
year os | 112 |
year old | 112 |
neopterin levels | 111 |
platelet engraftment | 110 |
disease status | 110 |
significantly reduced | 110 |
intracerebral hemorrhage | 110 |
well tolerated | 109 |
univariate analysis | 109 |
viral infections | 109 |
neutrophil engraftment | 108 |
single center | 108 |
epithelial cells | 107 |
present study | 106 |
tumor necrosis | 106 |
performed using | 106 |
healthy donors | 106 |
immune cells | 105 |
patients underwent | 105 |
retrospective analysis | 104 |
cell dose | 104 |
progenitor cells | 104 |
among patients | 104 |
acute lymphoblastic | 104 |
cerebral edema | 104 |
cancer patients | 103 |
mortality rate | 102 |
infectious complications | 101 |
resonance imaging | 101 |
hematological malignancies | 100 |
important role | 99 |
significantly lower | 99 |
medical center | 99 |
brain barrier | 98 |
lymphoblastic leukemia | 98 |
patient developed | 98 |
viral infection | 98 |
body weight | 97 |
results suggest | 96 |
mesenchymal stem | 95 |
respiratory distress | 95 |
cd ra | 95 |
monoclonal antibody | 95 |
whole blood | 94 |
matched sibling | 94 |
significantly increased | 94 |
patient died | 94 |
critical care | 93 |
cmv infection | 92 |
brain tissue | 92 |
cell proliferation | 92 |
brain death | 91 |
retrospectively analyzed | 91 |
protein concentration | 91 |
aplastic anemia | 91 |
six patients | 91 |
mass spectrometry | 90 |
poor prognosis | 90 |
haematopoietic stem | 90 |
case series | 90 |
matched related | 89 |
sibling donor | 89 |
immune responses | 88 |
seven patients | 88 |
acute phase | 88 |
mixed chimerism | 88 |
cell surface | 87 |
granulocyte colony | 87 |
nitric oxide | 87 |
trem variants | 87 |
infectious peritonitis | 87 |
first days | 87 |
cell depletion | 87 |
clinical features | 87 |
respiratory syndrome | 87 |
ill patients | 87 |
viral load | 87 |
colony stimulating | 86 |
transmission electron | 86 |
macrophage colony | 86 |
high levels | 86 |
patients transplanted | 86 |
hsct recipients | 86 |
feline infectious | 86 |
prostate cancer | 85 |
blood cell | 85 |
total body | 85 |
acute ischemic | 85 |
median duration | 85 |
age years | 85 |
hodgkin lymphoma | 85 |
healthy controls | 84 |
chronic graft | 84 |
year overall | 84 |
alveolar macrophages | 84 |
trem expression | 84 |
clinical course | 83 |
haploidentical donor | 83 |
usa introduction | 83 |
cohort study | 83 |
united states | 83 |
within days | 83 |
cells kg | 83 |
blood cells | 83 |
cancer cell | 83 |
survival rate | 82 |
doc id | 82 |
informed consent | 82 |
pts received | 82 |
cord uid | 82 |
nk cell | 82 |
mycophenolate mofetil | 82 |
cell death | 82 |
cytokine production | 82 |
ct scan | 82 |
renal failure | 81 |
extracellular vesicle | 81 |
relapse rate | 81 |
csf samples | 81 |
animal models | 81 |
recipient cells | 80 |
time points | 80 |
partial response | 80 |
progressive disease | 80 |
lumbar puncture | 80 |
least one | 79 |
umbilical cord | 79 |
plasma levels | 79 |
grade i | 79 |
cell culture | 79 |
serum levels | 79 |
icu admission | 79 |
inflammatory cytokines | 79 |
exclusion chromatography | 79 |
eight patients | 79 |
chain reaction | 78 |
septic patients | 78 |
low dose | 77 |
prospective study | 77 |
regression analysis | 76 |
one year | 76 |
complete response | 76 |
polymerase chain | 76 |
analysis showed | 76 |
response rate | 75 |
myelodysplastic syndrome | 75 |
aml patients | 75 |
old male | 75 |
may lead | 75 |
reactive protein | 75 |
findings suggest | 75 |
cell therapy | 75 |
cell counts | 74 |
patients showed | 74 |
patient received | 74 |
adhesion molecules | 74 |
lymph nodes | 74 |
risk patients | 74 |
significantly different | 73 |
statistical analysis | 73 |
derived exosomes | 73 |
mouse model | 73 |
mm hg | 73 |
intracranial hemorrhage | 73 |
coronavirus disease | 73 |
copies ml | 72 |
post transplant | 72 |
wound healing | 72 |
nine patients | 72 |
distress syndrome | 72 |
monoclonal antibodies | 72 |
white blood | 71 |
clinical outcome | 71 |
blood mononuclear | 71 |
medical records | 71 |
cryptococcal meningitis | 71 |
alveolar proteinosis | 71 |
mental status | 71 |
western blotting | 71 |
basic protein | 71 |
multiple organ | 70 |
partial remission | 70 |
chart review | 70 |
patients suffering | 70 |
functional outcome | 70 |
total protein | 70 |
statistical significance | 70 |
body irradiation | 70 |
infected patients | 70 |
line therapy | 69 |
hospital mortality | 69 |
mm patients | 69 |
may occur | 69 |
csf analysis | 69 |
full donor | 69 |
derived extracellular | 69 |
mast cells | 69 |
based conditioning | 69 |
sah patients | 68 |
autoimmune diseases | 68 |
recent studies | 68 |
blood cultures | 68 |
median cd | 68 |
significant increase | 68 |
residual disease | 68 |
two cases | 68 |
related donor | 67 |
respiratory tract | 67 |
identical sibling | 67 |
computed tomography | 67 |
previous studies | 67 |
transplant related | 67 |
platelet count | 67 |
plasma samples | 67 |
adverse effects | 67 |
patients presented | 67 |
may contribute | 66 |
head ct | 66 |
one case | 66 |
hematologic malignancies | 66 |
glasgow coma | 66 |
healthy volunteers | 66 |
modified rankin | 65 |
nasal polyps | 65 |
type i | 65 |
previously described | 65 |
stromal cells | 65 |
aneurysmal subarachnoid | 65 |
also found | 65 |
clinical characteristics | 64 |
study period | 64 |
iv acute | 64 |
increased levels | 64 |
higher risk | 64 |
size exclusion | 64 |
old female | 63 |
disease relapse | 63 |
clinical data | 63 |
clinical outcomes | 63 |
treatment option | 63 |
declare background | 63 |
good outcome | 63 |
determine whether | 63 |
donor lymphocyte | 63 |
inclusion criteria | 63 |
red blood | 62 |
brain mri | 62 |
cerebral blood | 62 |
phase ii | 62 |
allogeneic transplantation | 62 |
patient population | 62 |
significant reduction | 62 |
day post | 62 |
cell activation | 62 |
neurological complications | 62 |
specific antibodies | 62 |
intracranial hypertension | 62 |
died due | 62 |
commonly used | 62 |
brain edema | 62 |
bacterial infections | 61 |
allogeneic sct | 61 |
influenza virus | 61 |
patients may | 61 |
results indicate | 61 |
retrospectively reviewed | 61 |
mri brain | 61 |
pilot study | 61 |
cytokine release | 61 |
organ dysfunction | 61 |
analysis revealed | 61 |
gvhd grade | 61 |
case reports | 61 |
natural killer | 61 |
cell depleted | 61 |
disease free | 61 |
relapsed refractory | 61 |
prospective studies | 60 |
transplant cyclophosphamide | 60 |
may result | 60 |
higher incidence | 60 |
active disease | 60 |
may help | 60 |
patients aged | 60 |
old woman | 60 |
host defense | 60 |
donor type | 60 |
adhesion molecule | 59 |
immunosuppressive therapy | 59 |
ev isolation | 59 |
transplant recipients | 59 |
disease severity | 59 |
clinical practice | 59 |
prophylaxis consisted | 59 |
head injury | 59 |
cytokine storm | 59 |
mg ml | 59 |
tumor cells | 58 |
phase i | 58 |
days later | 58 |
treated patients | 58 |
myeloma patients | 58 |
graft rejection | 58 |
cerebral perfusion | 58 |
neurological symptoms | 58 |
stroke patients | 58 |
density gradient | 58 |
future studies | 58 |
cerebral ischemia | 58 |
endothelial cell | 57 |
cells ml | 57 |
patients achieved | 57 |
autologous hsct | 57 |
viral meningitis | 57 |
tumour cells | 57 |
rheumatoid arthritis | 57 |
previously reported | 57 |
first hours | 57 |
last follow | 57 |
surface markers | 57 |
salvage therapy | 56 |
neurological manifestations | 56 |
ten patients | 56 |
included patients | 56 |
old man | 56 |
myeloid cell | 56 |
first time | 56 |
pulmonary alveolar | 56 |
observational study | 56 |
neurological examination | 56 |
lung cancer | 56 |
cell viability | 56 |
early diagnosis | 56 |
major cause | 55 |
differential diagnosis | 55 |
patients presenting | 55 |
smooth muscle | 55 |
may play | 55 |
significantly decreased | 55 |
lymphoma patients | 55 |
weight loss | 55 |
csf protein | 55 |
cd count | 55 |
differentially expressed | 55 |
transplanted patients | 55 |
immune cell | 55 |
autologous hematopoietic | 55 |
induction therapy | 54 |
infectious diseases | 54 |
amino acid | 54 |
cerebral artery | 54 |
emergency department | 54 |
per cent | 54 |
independently associated | 54 |
primary outcome | 54 |
coma scale | 54 |
severe sepsis | 54 |
widely used | 54 |
csf levels | 54 |
tbi patients | 54 |
first line | 54 |
elevated levels | 54 |
fungal infections | 53 |
marrow transplant | 53 |
nucleated cells | 53 |
patients experienced | 53 |
occlusive disease | 53 |
target cells | 53 |
regression model | 53 |
hemorrhagic cystitis | 53 |
supportive care | 53 |
first year | 53 |
measured using | 53 |
underlying disease | 53 |
renal function | 53 |
clinical presentation | 53 |
retrospective review | 52 |
retrospective chart | 52 |
sample size | 52 |
platelet recovery | 52 |
acute lung | 52 |
inflammatory responses | 52 |
protein levels | 52 |
per day | 52 |
factors associated | 52 |
tissue damage | 52 |
mg day | 52 |
small rna | 52 |
year period | 52 |
generation sequencing | 52 |
common cause | 52 |
elderly patients | 51 |
clinical symptoms | 51 |
critical illness | 51 |
size distribution | 51 |
may provide | 51 |
conditioned media | 51 |
deficient mice | 51 |
underwent allogeneic | 51 |
one cat | 51 |
herpes simplex | 51 |
studies suggest | 51 |
ebv reactivation | 51 |
skeletal muscle | 51 |
class ii | 50 |
diagnostic criteria | 50 |
physical examination | 50 |
systematic review | 50 |
median days | 50 |
escherichia coli | 50 |
cell subsets | 50 |
significant improvement | 50 |
type ii | 50 |
higher levels | 50 |
patients engrafted | 50 |
study group | 50 |
developed acute | 49 |
trend towards | 49 |
neutrophil recovery | 49 |
fungal infection | 49 |
predictive value | 49 |
minimal residual | 49 |
tyrosine kinase | 49 |
high mortality | 49 |
risk group | 49 |
data indicate | 49 |
recombinant human | 49 |
apache ii | 49 |
hospital stay | 49 |
antifungal therapy | 48 |
receptor expressed | 48 |
triggering receptor | 48 |
sos vod | 48 |
neurological signs | 48 |
elevated protein | 48 |
malignant disease | 48 |
cd kg | 48 |
acute brain | 48 |
clinical studies | 48 |
weighted images | 48 |
neurological deficits | 48 |
controlled trial | 48 |
class i | 48 |
hypertonic saline | 48 |
haploidentical transplantation | 48 |
relapse incidence | 48 |
undergoing allogeneic | 48 |
small extracellular | 47 |
invasive fungal | 47 |
results demonstrate | 47 |
poorly understood | 47 |
hla matched | 47 |
haploidentical donors | 47 |
immunodeficiency virus | 47 |
differential ultracentrifugation | 47 |
therapeutic hypothermia | 46 |
median day | 46 |
oxidative stress | 46 |
haploidentical hsct | 46 |
underwent allo | 46 |
time point | 46 |
positive cells | 46 |
identified patients | 46 |
poor outcomes | 46 |
kg bw | 46 |
underwent hsct | 46 |
severe tbi | 46 |
solid tumors | 46 |
novel coronavirus | 46 |
median os | 46 |
key role | 46 |
significantly better | 46 |
curative treatment | 46 |
related complications | 45 |
barr virus | 45 |
day mortality | 45 |
retrospective cohort | 45 |
innate immune | 45 |
remaining patients | 45 |
extracellular matrix | 45 |
inflammatory diseases | 45 |
nucleic acids | 45 |
proinflammatory cytokines | 45 |
also observed | 45 |
rankin scale | 45 |
results show | 45 |
abdominal pain | 45 |
regimen consisted | 45 |
neutropenia recovery | 45 |
iv agvhd | 45 |
three groups | 45 |
ct scans | 45 |
prognostic factors | 45 |
conditioned medium | 45 |
confidence interval | 45 |
ev markers | 44 |
elevated icp | 44 |
disease control | 44 |
paediatric patients | 44 |
term follow | 44 |
effective treatment | 44 |
cell population | 44 |
isolated evs | 44 |
nucleated cell | 44 |
kg cd | 44 |
antithymocyte globulin | 44 |
cell function | 44 |
serum samples | 44 |
injured patients | 44 |
mri showed | 44 |
term outcome | 44 |
evs derived | 44 |
urinary tract | 44 |
symptom onset | 44 |
consecutive days | 44 |
mouse models | 44 |
animal model | 44 |
monocytes macrophages | 44 |
ad patients | 44 |
cryptococcus neoformans | 44 |
melphalan mg | 43 |
peripheral stem | 43 |
cell type | 43 |
liquid biopsy | 43 |
refractory disease | 43 |
cognitive impairment | 43 |
progression free | 43 |
antibiotic therapy | 43 |
autologous transplantation | 43 |
respiratory symptoms | 43 |
intercellular communication | 43 |
graft source | 43 |
myocardial infarction | 43 |
total number | 43 |
undergoing hsct | 43 |
sibling donors | 43 |
marrow failure | 43 |
months later | 43 |
allogeneic hct | 43 |
patients diagnosed | 43 |
cell mobilization | 43 |
atg group | 43 |
developed grade | 43 |
ev cargo | 43 |
post hsct | 43 |
bacterial infection | 43 |
normal range | 43 |
gastrointestinal tract | 43 |
infected cats | 43 |
transcription factor | 42 |
first case | 42 |
external ventricular | 42 |
effector cells | 42 |
significant correlation | 42 |
amino acids | 42 |
mrna expression | 42 |
recent study | 42 |
extensive chronic | 42 |
altered mental | 42 |
line treatment | 42 |
one study | 42 |
two cats | 42 |
severe chronic | 42 |
cd expression | 42 |
cns infection | 42 |
twice daily | 42 |
fl ammatory | 42 |
release syndrome | 42 |
hours post | 42 |
body temperature | 42 |
fludarabine mg | 41 |
center experience | 41 |
autologous peripheral | 41 |
thymocyte globulin | 41 |
sickle cell | 41 |
wild type | 41 |
culture media | 41 |
patients compared | 41 |
ev release | 41 |
assessed using | 41 |
blood volume | 41 |
mass effect | 41 |
refractory status | 41 |
medical history | 41 |
patient care | 41 |
syndrome coronavirus | 41 |
eosinophilic esophagitis | 41 |
mcg kg | 41 |
central venous | 41 |
therapeutic approach | 41 |
maintenance therapy | 41 |
mismatched unrelated | 41 |
preliminary results | 40 |
inflammatory mediators | 40 |
bronchoalveolar lavage | 40 |
dendritic cell | 40 |
natural history | 40 |
significantly improved | 40 |
studies showed | 40 |
heart rate | 40 |
may cause | 40 |
lyme disease | 40 |
systemic inflammatory | 40 |
surgical intervention | 40 |
six months | 40 |
received myeloablative | 40 |
mortality rates | 40 |
one patients | 40 |
intraventricular hemorrhage | 40 |
protein content | 40 |
old girl | 40 |
hospital discharge | 40 |
stable disease | 40 |
extracorporeal photopheresis | 40 |
cell adhesion | 40 |
even though | 40 |
patients will | 40 |
preliminary data | 39 |
leading cause | 39 |
results showed | 39 |
immune activation | 39 |
respiratory syncytial | 39 |
data show | 39 |
two different | 39 |
neurologic complications | 39 |
patient characteristics | 39 |
myelin basic | 39 |
one hundred | 39 |
immunocompromised patients | 39 |
allogeneic haematopoietic | 39 |
basal ganglia | 39 |
culture medium | 39 |
arterial blood | 39 |
gold standard | 39 |
evs isolated | 39 |
lung function | 39 |
old boy | 39 |
gram negative | 39 |
agvhd grade | 39 |
cerebral vasospasm | 39 |
neutropenic fever | 39 |
integrin expression | 39 |
cell populations | 38 |
antifungal prophylaxis | 38 |
time pcr | 38 |
matched donor | 38 |
analyzed using | 38 |
granulocyte macrophage | 38 |
recent years | 38 |
healthy subjects | 38 |
gray matter | 38 |
patient age | 38 |
treatment related | 38 |
safety profile | 38 |
clinical manifestations | 38 |
term survival | 38 |
factor receptor | 38 |
ich patients | 38 |
cord injury | 38 |
second line | 38 |
progenitor cell | 38 |
significantly elevated | 38 |
glasgow outcome | 38 |
family donor | 38 |
mhc class | 38 |
differential centrifugation | 38 |
haploidentical transplant | 38 |
overall response | 38 |
csf treatment | 38 |
survival rates | 38 |
protein expression | 38 |
hemorrhagic shock | 38 |
severe aplastic | 38 |
three times | 38 |
less likely | 38 |
may represent | 38 |
baseline characteristics | 38 |
middle cerebral | 38 |
evs released | 37 |
csf neopterin | 37 |
newly diagnosed | 37 |
younger patients | 37 |
brain parenchyma | 37 |
syncytial virus | 37 |
blood culture | 37 |
disease activity | 37 |
tract infection | 37 |
neutrophil count | 37 |
fold increase | 37 |
animal studies | 37 |
th cells | 37 |
per patient | 37 |
wide range | 37 |
grade iv | 37 |
isolation methods | 37 |
arterial pressure | 37 |
cells infused | 37 |
clinical improvement | 37 |
mean arterial | 37 |
autologous sct | 37 |
hiv infection | 37 |
ich score | 37 |
within months | 37 |
human eosinophils | 37 |
brain stem | 37 |
protective effect | 37 |
icu los | 37 |
tnf production | 36 |
organ damage | 36 |
reactive oxygen | 36 |
potential role | 36 |
transplant patients | 36 |
patients relapsed | 36 |
older patients | 36 |
cell disease | 36 |
subarachnoid space | 36 |
fold higher | 36 |
two weeks | 36 |
hospital admission | 36 |
achieved cr | 36 |
blood count | 36 |
aged years | 36 |
isolated using | 36 |
exact test | 36 |
family members | 36 |
primary endpoint | 36 |
hematoma expansion | 36 |
definitive diagnosis | 36 |
underwent asct | 36 |
odds ratio | 36 |
hsct patients | 36 |
hypereosinophilic syndrome | 36 |
lymphocyte infusion | 36 |
vs days | 36 |
diffuse large | 36 |
measles virus | 36 |
significant association | 36 |
cd positive | 36 |
visual acuity | 36 |
iav infection | 36 |
related toxicity | 36 |
therapeutic option | 36 |
study aimed | 36 |
literature review | 36 |
high doses | 36 |
infectious disease | 36 |
main cause | 36 |
neurological disease | 36 |
receptor antagonist | 36 |
still alive | 36 |
severe cgvhd | 36 |
cns disease | 36 |
remains unclear | 36 |
liver failure | 36 |
febrile neutropenia | 36 |
study included | 36 |
significant risk | 35 |
one week | 35 |
commercially available | 35 |
secondary graft | 35 |
severe traumatic | 35 |
pcr testing | 35 |
low levels | 35 |
tissue injury | 35 |
median dose | 35 |
disclosure background | 35 |
taken together | 35 |
plasma evs | 35 |
first day | 35 |
significantly correlated | 35 |
surface area | 35 |
three months | 35 |
mesenchymal stromal | 35 |
lung tissue | 35 |
viral reactivation | 35 |
hla identical | 35 |
new york | 35 |
related donors | 35 |
ovarian cancer | 35 |
primary graft | 35 |
autoimmune encephalomyelitis | 35 |
chemotherapy followed | 35 |
three different | 35 |
human brain | 35 |
cytokine levels | 35 |
heart failure | 35 |
csf administration | 35 |
therapeutic potential | 35 |
well known | 35 |
see chapter | 35 |
determined using | 35 |
thalassemia major | 35 |
developed severe | 35 |
vod sos | 34 |
induction chemotherapy | 34 |
ml min | 34 |
early detection | 34 |
older age | 34 |
curative option | 34 |
large number | 34 |
human herpesvirus | 34 |
clinically significant | 34 |
real time | 34 |
cell collection | 34 |
simplex virus | 34 |
inflammatory cells | 34 |
three days | 34 |
received hsct | 34 |
motor neuron | 34 |
per kg | 34 |
also showed | 34 |
limited data | 34 |
patient outcomes | 34 |
low risk | 34 |
clinical diagnosis | 34 |
west nile | 34 |
trauma patients | 34 |
significant decrease | 34 |
cells showed | 34 |
molecular mechanisms | 34 |
ev subpopulations | 34 |
surface expression | 34 |
colorectal cancer | 34 |
clinical response | 34 |
host cells | 34 |
leukemia patients | 34 |
infected mice | 34 |
cmv disease | 34 |
small number | 34 |
different types | 34 |
severe covid | 34 |
graft function | 34 |
amyotrophic lateral | 34 |
nd allo | 34 |
haploidentical stem | 34 |
well established | 34 |
group compared | 34 |
lateral sclerosis | 34 |
data suggests | 34 |
chronic myeloid | 33 |
cd depleted | 33 |
study showed | 33 |
immune suppression | 33 |
high incidence | 33 |
continuous infusion | 33 |
rna sequencing | 33 |
human immunodeficiency | 33 |
independent predictor | 33 |
also significantly | 33 |
multivariable analysis | 33 |
health care | 33 |
innate immunity | 33 |
viral encephalitis | 33 |
study shows | 33 |
plasma membrane | 33 |
plasma exchange | 33 |
malignant diseases | 33 |
prospectively collected | 33 |
collected data | 33 |
expression levels | 33 |
wbc count | 33 |
calculated using | 33 |
myeloid leukaemia | 33 |
cns involvement | 33 |
cyclophosphamide mg | 33 |
increased expression | 33 |
medical university | 33 |
control subjects | 33 |
therapeutic strategies | 33 |
replacement therapy | 33 |
icu patients | 33 |
cgvhd patients | 33 |
two days | 32 |
randomized trial | 32 |
blood glucose | 32 |
toxoplasma gondii | 32 |
serum neopterin | 32 |
cryptococcal infection | 32 |
presenting cells | 32 |
vascular endothelial | 32 |
csf pleocytosis | 32 |
trem deficient | 32 |
beneficial effects | 32 |
positive results | 32 |
bal fluid | 32 |
combination therapy | 32 |
clinical significance | 32 |
relapse free | 32 |
second transplant | 32 |
three cats | 32 |
liver function | 32 |
significant impact | 32 |
last years | 32 |
normal csf | 32 |
bk virus | 32 |
cns infections | 32 |
experimental autoimmune | 32 |
acute renal | 32 |
phase iii | 32 |
one month | 32 |
pts died | 32 |
eleven patients | 32 |
outcome scale | 32 |
spf cats | 32 |
showed significant | 32 |
outcome measures | 32 |
disease risk | 32 |
elevated serum | 32 |
patients included | 32 |
pulmonary toxicity | 32 |
may serve | 32 |
csf may | 32 |
transplant outcomes | 32 |
tumour microenvironment | 32 |
dependent manner | 32 |
like receptor | 32 |
life threatening | 32 |
national university | 32 |
autoimmune disease | 32 |
mononuclear cell | 31 |
csf receptor | 31 |
successfully treated | 31 |
general population | 31 |
exclusion criteria | 31 |
multicenter study | 31 |
similar results | 31 |
icu stay | 31 |
enrolled patients | 31 |
central role | 31 |
subdural hematoma | 31 |
salvage treatment | 31 |
achieved complete | 31 |
canine distemper | 31 |
gvhd occurred | 31 |
patients required | 31 |
lymphocyte infusions | 31 |
fi rst | 31 |
refractory acute | 31 |
acute disseminated | 31 |
signal transduction | 31 |
cranial nerve | 31 |
neurological outcome | 31 |
clinical study | 31 |
authors declare | 31 |
broad spectrum | 31 |
next generation | 31 |
cd ro | 31 |
serum glucose | 31 |
delayed cerebral | 31 |
steroid treatment | 31 |
disease course | 31 |
body surface | 31 |
small evs | 31 |
cell communication | 31 |
total nucleated | 31 |
rank test | 31 |
acute encephalitis | 31 |
cell responses | 31 |
following allogeneic | 31 |
allogeneic bone | 31 |
first study | 31 |
clinically relevant | 31 |
patients affected | 31 |
pd patients | 31 |
protein cargo | 31 |
perfusion pressure | 31 |
infected cells | 31 |
cells may | 31 |
stage iii | 31 |
nasal polyposis | 30 |
risk acute | 30 |
blot analysis | 30 |
immunosuppressive treatment | 30 |
transplant period | 30 |
current study | 30 |
fever without | 30 |
donor cells | 30 |
asah patients | 30 |
also known | 30 |
care units | 30 |
another study | 30 |
ab mbp | 30 |
human monocytes | 30 |
pseudomonas aeruginosa | 30 |
tract infections | 30 |
abdominal sepsis | 30 |
analysed using | 30 |
functional outcomes | 30 |
lymph node | 30 |
received allo | 30 |
may reflect | 30 |
protein concentrations | 30 |
studies will | 30 |
tumour growth | 30 |
negative bacteria | 30 |
vitro studies | 30 |
several studies | 30 |
term outcomes | 30 |
steroid refractory | 30 |
better os | 30 |
without fip | 30 |
corpus callosum | 30 |
financial support | 30 |
human granulocyte | 30 |
high morbidity | 30 |
inflammatory monocytes | 30 |
cells per | 30 |
year cumulative | 30 |
mg daily | 30 |
patient presented | 30 |
thermal injury | 30 |
crucial role | 30 |
therapeutic strategy | 30 |
healthy individuals | 30 |
binding protein | 30 |
oxygen saturation | 30 |
trial registry | 30 |
family history | 30 |
surface marker | 30 |
neurological disorders | 30 |
median survival | 30 |
favorable outcome | 30 |
barrier function | 29 |
complete resolution | 29 |
autoimmune encephalitis | 29 |
ml kg | 29 |
female patients | 29 |
hct recipients | 29 |
response rates | 29 |
significant morbidity | 29 |
complete blood | 29 |
cell numbers | 29 |
total rna | 29 |
kg body | 29 |
nucleic acid | 29 |
time course | 29 |
developmental delay | 29 |
linked immunosorbent | 29 |
immune deficiency | 29 |
carotid artery | 29 |
quantitative pcr | 29 |
adaptive immune | 29 |
may present | 29 |
patient showed | 29 |
cell carcinoma | 29 |
exosomes derived | 29 |
lavage fluid | 29 |
early post | 29 |
increased mortality | 29 |
red cell | 29 |
hess grade | 29 |
ev production | 29 |
study population | 29 |
dose therapy | 29 |
nile virus | 29 |
short course | 29 |
quality control | 29 |
salvage chemotherapy | 29 |
using flow | 29 |
per week | 29 |
mobilized peripheral | 29 |
within weeks | 29 |
cerebrovascular disease | 29 |
critical role | 29 |
cardiac output | 29 |
including patients | 29 |
ev numbers | 29 |
antibiotic treatment | 29 |
response syndrome | 29 |
cats without | 29 |
specific antibody | 29 |
gram stain | 29 |
cerebral infarction | 28 |
received allogeneic | 28 |
bacterial translocation | 28 |
developed chronic | 28 |
previously shown | 28 |
elevated csf | 28 |
solid organ | 28 |
following hsct | 28 |
one child | 28 |
disseminated encephalomyelitis | 28 |
treatment options | 28 |
care patients | 28 |
decision making | 28 |
within minutes | 28 |
cell growth | 28 |
inflammatory process | 28 |
beneficial effect | 28 |
significant changes | 28 |
many patients | 28 |
curative therapy | 28 |
performance status | 28 |
age group | 28 |
mri findings | 28 |
infused cd | 28 |
therapy may | 28 |
kidney injury | 28 |
circulating evs | 28 |
major basic | 28 |
university medical | 28 |
intravenous immunoglobulin | 28 |
one third | 28 |
brain imaging | 28 |
high resolution | 28 |
intestinal gvhd | 28 |
cord compression | 28 |
patient cohort | 28 |
patients following | 28 |
biological activity | 28 |
without source | 28 |
eosinophilic myositis | 28 |
fully matched | 28 |
studies using | 28 |
previously published | 28 |
every hours | 28 |
single centre | 28 |
protein markers | 28 |
flow cytometric | 28 |
discharged home | 28 |
mcg ml | 28 |
ii score | 28 |
mds patients | 28 |
different cell | 28 |
study suggests | 28 |
cells transplantation | 28 |
study aims | 28 |
complement activation | 28 |
preparative regimen | 28 |
aneurysmal sah | 28 |
allogeneic transplant | 28 |
jazz pharmaceuticals | 28 |
liver disease | 28 |
aseptic meningitis | 28 |
may benefit | 27 |
late effects | 27 |
conditioning therapy | 27 |
month period | 27 |
donor cell | 27 |
particle size | 27 |
inflammatory processes | 27 |
retrospectively evaluated | 27 |
axonal injury | 27 |
per ml | 27 |
transcranial doppler | 27 |
neutrophilic pleocytosis | 27 |
standard deviation | 27 |
blood transplantation | 27 |
days vs | 27 |
proteomic analysis | 27 |
median interval | 27 |
comatose patients | 27 |
muscle biopsy | 27 |
oligoclonal bands | 27 |
compared using | 27 |
obstruction syndrome | 27 |
palliative care | 27 |
patients infected | 27 |
beam group | 27 |
data regarding | 27 |
engraftment occurred | 27 |
antibody titers | 27 |
two years | 27 |
allograft rejection | 27 |
mechanically ventilated | 27 |
mean time | 27 |
newborn babies | 27 |
burst suppression | 27 |
increased intracranial | 27 |
wistar rats | 27 |
mast cell | 27 |
treated group | 27 |
dc leu | 27 |
male patients | 27 |
research funding | 27 |
positive patients | 27 |
reperfusion injury | 27 |
severe gvhd | 27 |
trauma center | 27 |
showed significantly | 27 |
without significant | 27 |
ethics committee | 27 |
treatment group | 27 |
severe brain | 27 |
advanced disease | 27 |
second patient | 27 |
better outcome | 27 |
cell receptor | 27 |
evidence suggests | 27 |
early stage | 27 |
gi tract | 27 |
new therapeutic | 27 |
improve outcomes | 27 |
transforming growth | 27 |
tumour progression | 27 |
seasonal influenza | 27 |
pathway analysis | 27 |
positive correlation | 27 |
month follow | 27 |
olfactory sensory | 27 |
i ii | 27 |
side effect | 27 |
peripheral nervous | 27 |
multiorgan failure | 27 |
acute encephalopathy | 27 |
identify patients | 27 |
data collection | 27 |
cryptococcal antigen | 26 |
tertiary care | 26 |
post asct | 26 |
oxygen species | 26 |
lymphocyte count | 26 |
patients whose | 26 |
venous blood | 26 |
blood transfusion | 26 |
trend toward | 26 |
entire cohort | 26 |
midline shift | 26 |
chemokine receptor | 26 |
patient underwent | 26 |
epithelial cell | 26 |
neurodegenerative diseases | 26 |
multivariable logistic | 26 |
th day | 26 |
progressive ms | 26 |
adipose tissue | 26 |
severe neutropenia | 26 |
cell recovery | 26 |
centre experience | 26 |
upper respiratory | 26 |
analyzed patients | 26 |
immunosorbent assay | 26 |
strongly associated | 26 |
dnase activity | 26 |
vasogenic edema | 26 |
arterial hypertension | 26 |
prognostic factor | 26 |
may show | 26 |
staphylococcus aureus | 26 |
ich volume | 26 |
hypoxic respiratory | 26 |
total dose | 26 |
evoked potentials | 26 |
differential expression | 26 |
inflammatory cytokine | 26 |
times higher | 26 |
potential therapeutic | 26 |
high rate | 26 |
inflammatory disease | 26 |
single dose | 26 |
potentially curative | 26 |
ventricular drain | 26 |
matter lesions | 26 |
less common | 26 |
cells expressing | 26 |
patient group | 26 |
patients suffered | 26 |
age groups | 26 |
data support | 26 |
scoring system | 25 |
alternative donor | 25 |
randomized controlled | 25 |
chimeric antigen | 25 |
cd dose | 25 |
cellular uptake | 25 |
renal disease | 25 |
acute stroke | 25 |
severe cases | 25 |
cells treated | 25 |
sinusoidal obstruction | 25 |
producing cells | 25 |
small sample | 25 |
family donors | 25 |
laboratory tests | 25 |
clinical deterioration | 25 |
poor graft | 25 |
biological activities | 25 |
autosomal recessive | 25 |
alveolar epithelial | 25 |
mechanisms underlying | 25 |
placebo group | 25 |
national institutes | 25 |
time period | 25 |
flow cytometer | 25 |
national institute | 25 |
intervertebral disc | 25 |
electronic medical | 25 |
year survival | 25 |
mri scans | 25 |
may explain | 25 |
neutrophil counts | 25 |
short term | 25 |
acute necrotizing | 25 |
regression models | 25 |
significantly greater | 25 |
steroid therapy | 25 |
longer follow | 25 |
hospital day | 25 |
virus infections | 25 |
fatty acids | 25 |
studied patients | 25 |
urinary neopterin | 25 |
eosinophil infiltration | 25 |
granule proteins | 25 |
first dose | 25 |
monocyte differentiation | 25 |
post sct | 25 |
complete donor | 25 |
eosinophils may | 25 |
overall mortality | 25 |
eosinophil recruitment | 25 |
optic nerve | 25 |
antiviral therapy | 25 |
absolute neutrophil | 25 |
medical management | 25 |
novel therapeutic | 25 |
parenteral nutrition | 25 |
blood vessels | 25 |
weight gain | 25 |
post transplantation | 25 |
first complete | 25 |
like receptors | 25 |
cell lung | 25 |
likely due | 25 |
lymphocytic leukemia | 25 |
sensory neurons | 25 |
improved survival | 25 |
survival time | 25 |
immune function | 25 |
rat model | 24 |
well understood | 24 |
induced neutropenia | 24 |
average age | 24 |
dose melphalan | 24 |
neurological diseases | 24 |
hematological recovery | 24 |
wide variety | 24 |
twelve patients | 24 |
neutrophil extracellular | 24 |
neuro icu | 24 |
major complication | 24 |
early stages | 24 |
times per | 24 |
common complication | 24 |
reconstitution inflammatory | 24 |
vivo studies | 24 |
interquartile range | 24 |
blood monocytes | 24 |
acute onset | 24 |
systolic blood | 24 |
unknown origin | 24 |
second hsct | 24 |
oral mucositis | 24 |
least two | 24 |
hazard ratio | 24 |
comorbidity index | 24 |
system involvement | 24 |
drug resistance | 24 |
imaging findings | 24 |
one hour | 24 |
mainly due | 24 |
human peripheral | 24 |
membrane vesicles | 24 |
haematological malignancies | 24 |
poor mobilizers | 24 |
leukemic cells | 24 |
spontaneous ich | 24 |
pivotal role | 24 |
demyelinating disease | 24 |
paediatric neurology | 24 |
cox regression | 24 |
years ago | 24 |
hospitalized patients | 24 |
also increased | 24 |
first month | 24 |
intermediate risk | 24 |
macrophage activation | 24 |
ecp treatment | 24 |
donor source | 24 |
male female | 24 |
first months | 24 |
analysis using | 24 |
liposomal amphotericin | 24 |
age range | 24 |
standard therapy | 24 |
major role | 24 |
cell number | 24 |
published data | 24 |
outcome measure | 24 |
inflammatory syndrome | 24 |
trem deficiency | 24 |
often associated | 24 |
examination showed | 24 |
eligible patients | 24 |
chronic lymphocytic | 24 |
brain showed | 24 |
feline coronavirus | 24 |
opening pressure | 24 |
therapeutic approaches | 24 |
csf group | 24 |
adverse event | 24 |
linear regression | 24 |
steady state | 24 |
assess whether | 24 |
influenza infection | 24 |
transverse myelitis | 24 |
samples collected | 24 |
viral replication | 24 |
muscle cells | 24 |
per year | 24 |
unrelated cord | 24 |
host response | 24 |
organ injury | 24 |
cell replete | 24 |
serum albumin | 24 |
kinase inhibitors | 24 |
patients requiring | 24 |
may improve | 24 |
remains unknown | 24 |
lymphocyte subsets | 24 |
days prior | 24 |
body fluids | 24 |
patient groups | 24 |
average time | 24 |
selected patients | 24 |
clinical background | 23 |
better understanding | 23 |
young patients | 23 |
protein level | 23 |
disease caused | 23 |
center study | 23 |
skin lesions | 23 |
may manifest | 23 |
nerve conduction | 23 |
mildly elevated | 23 |
antigen presentation | 23 |
several days | 23 |
cell differentiation | 23 |
cik cells | 23 |
uric acid | 23 |
successful treatment | 23 |
eosinophilic inflammation | 23 |
received peripheral | 23 |
results obtained | 23 |
coronavirus infection | 23 |
patients also | 23 |
abstract already | 23 |
lower incidence | 23 |
young children | 23 |
serum il | 23 |
group vs | 23 |
better understand | 23 |
adoptive transfer | 23 |
conventional chemotherapy | 23 |
currently available | 23 |
group patients | 23 |
calcineurin inhibitors | 23 |
higher rate | 23 |
molecular weight | 23 |
days following | 23 |
engraftment failure | 23 |
fluid analysis | 23 |
associated encephalopathy | 23 |
increased incidence | 23 |
lower extremity | 23 |
cell reconstitution | 23 |
hunt hess | 23 |
following treatment | 23 |
randomized clinical | 23 |
nasopharyngeal swab | 23 |
organ donation | 23 |
human plasma | 23 |
heat shock | 23 |
outcome data | 23 |
years post | 23 |
cytotoxic activity | 23 |
colonystimulating factor | 23 |
treatment strategies | 23 |
ad mouse | 23 |
active infection | 23 |
high grade | 23 |
independent risk | 23 |
relapsed disease | 23 |
choroid plexus | 23 |
better outcomes | 23 |
cerebral venous | 23 |
previous study | 23 |
chronic inflammatory | 23 |
chronic rhinosinusitis | 23 |
levels increased | 23 |
therapeutic effect | 23 |
highly sensitive | 23 |
investigate whether | 23 |
peritoneal macrophages | 23 |
disease process | 23 |
outer membrane | 23 |
gene therapy | 23 |
iu ml | 23 |
melanoma cells | 23 |
provide evidence | 23 |
data demonstrate | 23 |
clinical findings | 23 |
exosomes isolated | 23 |
barre syndrome | 23 |
particles ml | 23 |
multivariate logistic | 23 |
clinical information | 23 |
respiratory viruses | 23 |
lymphocytic pleocytosis | 23 |
already published | 23 |
control patients | 23 |
good partial | 23 |
culture system | 23 |
tumour cell | 23 |
higher rates | 23 |
donor age | 23 |
acute liver | 23 |
room temperature | 23 |
algan gan | 23 |
hematopoetic stem | 23 |
first patient | 23 |
burn injury | 23 |
nasal polyp | 23 |
three cases | 23 |
early phase | 23 |
three pts | 22 |
temporal lobe | 22 |
acute kidney | 22 |
ev preparations | 22 |
treatment modality | 22 |
groups according | 22 |
protein synthesis | 22 |
limited number | 22 |
aplastic anaemia | 22 |
gcs score | 22 |
standard treatment | 22 |
different time | 22 |
year follow | 22 |
associated pneumonia | 22 |
cell products | 22 |
normal saline | 22 |
thrombotic microangiopathy | 22 |
using standard | 22 |
year post | 22 |
times daily | 22 |
tumor cell | 22 |
retrospectively analysed | 22 |
based regimen | 22 |
female patient | 22 |
interim analysis | 22 |
extracellular traps | 22 |
atrial fibrillation | 22 |
seven days | 22 |
lps challenge | 22 |
mg twice | 22 |
neurological exam | 22 |
neurointensive care | 22 |
received dli | 22 |
controlled study | 22 |
mesenteric lymph | 22 |
posterior reversible | 22 |
analysis identified | 22 |
sodium chloride | 22 |
results confirm | 22 |
allogenic hematopoietic | 22 |
diagnostic yield | 22 |
negative sepsis | 22 |
cell survival | 22 |
sepsis syndrome | 22 |
also shown | 22 |
higher cd | 22 |
treated animals | 22 |
glial cells | 22 |
cox proportional | 22 |
expression level | 22 |
post allo | 22 |
consecutive adult | 22 |
ev protein | 22 |
cells mm | 22 |
chemotherapy alone | 22 |
may act | 22 |
least days | 22 |
two pts | 22 |
remained stable | 22 |
control groups | 22 |
evs may | 22 |
acute hypoxic | 22 |
clinical setting | 22 |
quality improvement | 22 |
diagnostic tests | 22 |
liver toxicity | 22 |
treated mice | 22 |
oxygen tension | 22 |
tissue repair | 22 |
encephalitis associated | 22 |
event free | 22 |
single ev | 22 |
kg iv | 22 |
free radicals | 22 |
male patient | 22 |
agvhd patients | 22 |
undergoing allo | 22 |
primary immunodeficiency | 22 |
hydrogen peroxide | 22 |
cell infusion | 22 |
ct head | 22 |
suspected meningitis | 22 |
normal human | 22 |
brain biopsy | 22 |
liver enzymes | 22 |
research center | 22 |
blood loss | 22 |
genetic testing | 22 |
adult respiratory | 22 |
independent predictors | 22 |
gel electrophoresis | 22 |
derived ev | 22 |
inflammatory bowel | 21 |
molecular remission | 21 |
iii iv | 21 |
serum sodium | 21 |
effector functions | 21 |
hematologic diseases | 21 |
acute pancreatitis | 21 |
adaptive immunity | 21 |
developed cmv | 21 |
apnea test | 21 |
fip cats | 21 |
invasive mechanical | 21 |
relapse rates | 21 |
th percentile | 21 |
well described | 21 |
genomic dna | 21 |
phase study | 21 |
five days | 21 |
rating scale | 21 |
higher mortality | 21 |
phase proteins | 21 |
body mass | 21 |
one day | 21 |
plasma concentrations | 21 |
diffusion restriction | 21 |
venous catheter | 21 |
study will | 21 |
olfactory bulb | 21 |
frontal lobe | 21 |
encephalitis virus | 21 |
brain ct | 21 |
macrophage polarization | 21 |
allergen challenge | 21 |
reduced toxicity | 21 |
apnea testing | 21 |
expression analysis | 21 |
tumor growth | 21 |
based regimens | 21 |
drug delivery | 21 |
viral rna | 21 |
serious adverse | 21 |
human metapneumovirus | 21 |
cell cultures | 21 |
specific immune | 21 |
associated acute | 21 |
blood eosinophilia | 21 |
low incidence | 21 |
icp monitoring | 21 |
mrd group | 21 |
new onset | 21 |
cmv viremia | 21 |
blood contamination | 21 |
also used | 21 |
pet ct | 21 |
heavily pretreated | 21 |
neurologic symptoms | 21 |
longer time | 21 |
cancer center | 21 |
white cell | 21 |
invasive aspergillosis | 21 |
platelet counts | 21 |
higher doses | 21 |
systemic lupus | 21 |
lower gi | 21 |
ev proteins | 21 |
heart disease | 21 |
neurologic manifestations | 21 |
received either | 21 |
cells compared | 21 |
final concentration | 21 |
endothelial damage | 21 |
showed increased | 21 |
positive csf | 21 |
investigated whether | 21 |
review board | 21 |
institutional review | 21 |
continuous eeg | 21 |
intensive chemotherapy | 21 |
stimulating factors | 21 |
early mortality | 21 |
induced lung | 21 |
cells using | 21 |
nhl patients | 21 |
frequently used | 21 |
endovascular treatment | 21 |
control animals | 21 |
evs showed | 21 |
normal controls | 21 |
cd ratio | 21 |
hours prior | 21 |
blood brain | 21 |
group will | 21 |
polysaccharide antigen | 21 |
systemic inflammation | 21 |
transgenic mice | 21 |
pao fio | 21 |
protective effects | 21 |
head trauma | 21 |
risk cytogenetics | 21 |
risk aml | 21 |
cumulative incidences | 21 |
ev populations | 21 |
guinea pigs | 21 |
culture conditions | 21 |
also demonstrated | 21 |
ev surface | 21 |
without evidence | 21 |
hematopoietic recovery | 21 |
lactate dehydrogenase | 21 |
lupus erythematosus | 21 |
serious complication | 21 |
conditioned patients | 21 |
neurological dysfunction | 21 |
additional studies | 21 |
clinical applications | 21 |
absolute number | 21 |
randomized study | 21 |
past medical | 20 |
also associated | 20 |
immune recovery | 20 |
transplant characteristics | 20 |
end point | 20 |
exosome secretion | 20 |
signaling pathway | 20 |
induction treatment | 20 |
increased il | 20 |
syndrome associated | 20 |
coronary artery | 20 |
high level | 20 |
airway inflammation | 20 |
worse outcomes | 20 |
written informed | 20 |
sputum eosinophils | 20 |
small cell | 20 |
severe infections | 20 |
seizure frequency | 20 |
probably due | 20 |
receptor expression | 20 |
whole lung | 20 |
csf mrna | 20 |
lower respiratory | 20 |
transplant complications | 20 |
dr expression | 20 |
severe complication | 20 |
movement disorders | 20 |
brain lesions | 20 |
syphilitic gumma | 20 |
johns hopkins | 20 |
markers cd | 20 |
antigen receptor | 20 |
naturally occurring | 20 |
patients enrolled | 20 |
preemptive therapy | 20 |
early death | 20 |
hsct setting | 20 |
may develop | 20 |
displaying pep | 20 |
prospective cohort | 20 |
years overall | 20 |
arterial verapamil | 20 |
transplant outcome | 20 |
positively correlated | 20 |
received chemotherapy | 20 |
severe disease | 20 |
small rnas | 20 |
specific cd | 20 |
years later | 20 |
control mice | 20 |
spinal trauma | 20 |
larger studies | 20 |
converting enzyme | 20 |
alveolar macrophage | 20 |
tested positive | 20 |
vital signs | 20 |
cancer institute | 20 |
optic neuritis | 20 |
possible role | 20 |
myelogenous leukemia | 20 |
rabbit atg | 20 |
primary refractory | 20 |
patients responded | 20 |
increased numbers | 20 |
retrospective case | 20 |
human disease | 20 |
relapse risk | 20 |
autologous transplant | 20 |
pts receiving | 20 |
clinical condition | 20 |
neutrophil elastase | 20 |
hospital los | 20 |
every weeks | 20 |
signalling pathways | 20 |
reversible encephalopathy | 20 |
eosinophilic infiltration | 20 |
underwent autologous | 20 |
spinal fluid | 20 |
pulse sensing | 20 |
inflammatory csf | 20 |
severe combined | 20 |
early intervention | 20 |
soft tissue | 20 |
cmv dna | 20 |
higher number | 20 |
cytogenetic risk | 20 |
hemorrhagic stroke | 20 |
autologous blood | 20 |
asthmatic subjects | 20 |
clinical use | 20 |
prospective randomized | 20 |
glucose levels | 20 |
thirteen patients | 20 |
will help | 20 |
cell migration | 20 |
secondary progressive | 20 |
killer cells | 20 |
study demonstrates | 20 |
increasingly used | 20 |
evd placement | 20 |
gvhd patients | 20 |
analysis included | 20 |
patients submitted | 20 |
tissue oxygen | 20 |
using anti | 20 |
last decade | 20 |
organ transplant | 20 |
differ significantly | 20 |
temperature management | 20 |
rabbit anti | 20 |
group received | 20 |
spectrum antibiotics | 20 |
promising results | 20 |
injury severity | 20 |
icu length | 20 |
data collected | 20 |
human coronavirus | 20 |
cns inflammation | 20 |
significant change | 20 |
tissue samples | 20 |
high affinity | 20 |
mean number | 20 |
studies demonstrated | 20 |
blood levels | 20 |
oxide synthase | 20 |
exome sequencing | 20 |
evaluated using | 20 |
cd selected | 20 |
immunosuppressive agents | 20 |
confocal microscopy | 20 |
refractory gvhd | 20 |
csf overexpression | 20 |
inflammatory demyelinating | 20 |
size range | 20 |
tumour necrosis | 20 |
ab tmev | 20 |
kinase inhibitor | 20 |
blood sample | 20 |
donor recipient | 20 |
fluorescence microscopy | 19 |
ev secretion | 19 |
posterior circulation | 19 |
transcription levels | 19 |
ev samples | 19 |
bu cy | 19 |
antigen presenting | 19 |
colony forming | 19 |
primary diagnosis | 19 |
neurological association | 19 |
great ormond | 19 |
related toxicities | 19 |
large evs | 19 |
allo hsct | 19 |
muscle weakness | 19 |
normal values | 19 |
csf strem | 19 |
developed agvhd | 19 |
based gvhd | 19 |
inflammatory reaction | 19 |
enterovirus pcr | 19 |
data showed | 19 |
therapeutic efficacy | 19 |
observational cohort | 19 |
necrotizing encephalopathy | 19 |
may affect | 19 |
complete recovery | 19 |
relapsed aml | 19 |
hi monocytes | 19 |
positive control | 19 |
remission status | 19 |
young people | 19 |
csf alone | 19 |
often used | 19 |
surviving patients | 19 |
studies show | 19 |
primary objective | 19 |
frequent complication | 19 |
neurologic disease | 19 |
dose dependent | 19 |
threatening complication | 19 |
useful tool | 19 |
affected cats | 19 |
except one | 19 |
relatively high | 19 |
pulmonary disease | 19 |
infection may | 19 |
may influence | 19 |
ormond street | 19 |
high prevalence | 19 |
may produce | 19 |
transcription factors | 19 |
severe respiratory | 19 |
patient experienced | 19 |
gvhd incidence | 19 |
treatment failure | 19 |
high expression | 19 |
fully understood | 19 |
associated proteins | 19 |
plerixafor group | 19 |
early relapse | 19 |
motor function | 19 |
blood stream | 19 |
dose cyclophosphamide | 19 |
csf showed | 19 |
infectious agents | 19 |
cd evs | 19 |
highly variable | 19 |
fourteen patients | 19 |
lumbar csf | 19 |
cell sources | 19 |
muscular dystrophy | 19 |
autologous hct | 19 |
blood donors | 19 |
alkaline phosphatase | 19 |
major histocompatibility | 19 |
one pt | 19 |
hematological diseases | 19 |
matrix metalloproteinase | 19 |
kidney disease | 19 |
control study | 19 |
post hct | 19 |
human patients | 19 |
will also | 19 |
chest radiograph | 19 |
brain injured | 19 |
severe agvhd | 19 |
evaluable patients | 19 |
biopsy specimens | 19 |
haploidentical hematopoietic | 19 |
lower limbs | 19 |
circulating neutrophils | 19 |
care society | 19 |
plasma cells | 19 |
blood eosinophils | 19 |
single cell | 19 |
every months | 19 |
ev size | 19 |
factors may | 19 |
function tests | 19 |
american neurological | 19 |
host immune | 19 |
contrast enhancement | 19 |
high sensitivity | 19 |
spot sign | 19 |
many studies | 19 |
healthy donor | 19 |
restricted diffusion | 19 |
ventilated patients | 19 |
eosinophil numbers | 19 |
weeks post | 19 |
statistical difference | 19 |
also reported | 19 |
mud mmud | 19 |
recently published | 19 |
hematopoietic cells | 19 |
increased icp | 19 |
treatment groups | 19 |
younger age | 19 |
refractory aml | 19 |
patients years | 19 |
treated cells | 19 |
identified using | 19 |
neutrophil survival | 19 |
wt mice | 19 |
hemophagocytic lymphohistiocytosis | 19 |
target temperature | 19 |
systemic treatment | 19 |
better survival | 19 |
complications associated | 19 |
graft vs | 19 |
cardiovascular disease | 19 |
median overall | 19 |
consolidation therapy | 19 |
blood group | 19 |
resistive pulse | 19 |
biological fluids | 19 |
correlation coefficient | 19 |
scan showed | 19 |
imaging studies | 19 |
plga nanoparticles | 19 |
cell membrane | 19 |
culture supernatant | 19 |
csf culture | 19 |
observation period | 19 |
kg i | 19 |
blood products | 18 |
respiratory virus | 18 |
liquid chromatography | 18 |
plasma cell | 18 |
significant predictors | 18 |
two decades | 18 |
medical record | 18 |
young adults | 18 |
received mg | 18 |
total evs | 18 |
internal carotid | 18 |
hepatocellular carcinoma | 18 |
may offer | 18 |
gi gvhd | 18 |
prospective observational | 18 |
borrelia burgdorferi | 18 |
lesser extent | 18 |
reactivation occurred | 18 |
national cancer | 18 |
neuronal cells | 18 |
signalling pathway | 18 |
therapeutic target | 18 |
will receive | 18 |
blood transfusions | 18 |
ko mice | 18 |
treatment strategy | 18 |
situ hybridization | 18 |
cecal ligation | 18 |
among others | 18 |
highly expressed | 18 |
prospectively enrolled | 18 |
stroke center | 18 |
clinical evaluation | 18 |
results will | 18 |
may require | 18 |
patient relapsed | 18 |
ventricular system | 18 |
significant effect | 18 |
internal medicine | 18 |
sinus thrombosis | 18 |
significant proportion | 18 |
bovine serum | 18 |
treatment response | 18 |
purified evs | 18 |
multiple trauma | 18 |
sars coronavirus | 18 |
virus type | 18 |
platelet activation | 18 |
risk score | 18 |
auto hsct | 18 |
eosinophil cationic | 18 |
arrest patients | 18 |
msc evs | 18 |
vascular smooth | 18 |
bowel disease | 18 |
cell cycle | 18 |
rights reserved | 18 |
three weeks | 18 |
allogenic hsct | 18 |
results support | 18 |
surgical decompression | 18 |
effective therapy | 18 |
diabetes mellitus | 18 |
platelet transfusions | 18 |
different ev | 18 |
csf serum | 18 |
different levels | 18 |
adverse reactions | 18 |
ev biogenesis | 18 |
endotracheal tube | 18 |
vascular endothelium | 18 |
cell activity | 18 |
lung disease | 18 |
risk features | 18 |
good response | 18 |
decompressive hemicraniectomy | 18 |
four cats | 18 |
respiratory insufficiency | 18 |
mortality due | 18 |
mediated immunity | 18 |
ms ms | 18 |
initial presentation | 18 |
los angeles | 18 |
may indicate | 18 |
data analysis | 18 |
rare complication | 18 |
without atg | 18 |
decreased expression | 18 |
clinical management | 18 |
largely unknown | 18 |
encephalopathy syndrome | 18 |
least months | 18 |
much less | 18 |
plasminogen activator | 18 |
group i | 18 |
idiopathic eosinophilic | 18 |
many different | 18 |
significant clinical | 18 |
recent data | 18 |
low level | 18 |
oxygen delivery | 18 |
pulmonary edema | 18 |
pb cd | 18 |
late onset | 18 |
high concentrations | 18 |
corticosteroid therapy | 18 |
may increase | 18 |
first week | 18 |
increased significantly | 18 |
dna damage | 18 |
public health | 18 |
detection limit | 18 |
eosinophil counts | 18 |
unclear whether | 18 |
lewis rats | 18 |
septic complications | 18 |
will provide | 18 |
refractory patients | 18 |
venous access | 18 |
patients met | 18 |
high index | 18 |
four weeks | 18 |
weighted imaging | 18 |
drug interactions | 18 |
improve survival | 18 |
previous reports | 18 |
homing peptide | 18 |
multicenter trial | 18 |
primary infection | 18 |
progressive multiple | 18 |
last dose | 18 |
organ involvement | 17 |
intraparenchymal hemorrhage | 17 |
expression profile | 17 |
hours following | 17 |
signaling pathways | 17 |
clinical samples | 17 |
patients survived | 17 |
previously healthy | 17 |
grade sah | 17 |
hepatic encephalopathy | 17 |
ev uptake | 17 |
cationic protein | 17 |
inhibitory effect | 17 |
nonrelapse mortality | 17 |
skin involvement | 17 |
ct angiogram | 17 |
two months | 17 |
lesions may | 17 |
specific markers | 17 |
commonly seen | 17 |
treatment may | 17 |
cd antibody | 17 |
hematological disorders | 17 |
blood progenitor | 17 |
daily dose | 17 |
electrographic seizures | 17 |
signal intensity | 17 |
weeks later | 17 |
markedly increased | 17 |
per month | 17 |
ccr expression | 17 |
autologous pbsct | 17 |
significant cause | 17 |
csf antibodies | 17 |
nmda receptor | 17 |
therapeutic options | 17 |
rare cases | 17 |
induced asthma | 17 |
matched controls | 17 |
visual loss | 17 |
phagocytic cells | 17 |
examination revealed | 17 |
infected animals | 17 |
venous thrombosis | 17 |
may induce | 17 |
poor quality | 17 |
cell mediated | 17 |
peripheral neuropathy | 17 |
risk stratification | 17 |
pts developed | 17 |
specific igg | 17 |
systemic signs | 17 |
children undergoing | 17 |
received bone | 17 |
receptor signaling | 17 |
three years | 17 |
meier method | 17 |
refractory agvhd | 17 |
group consisted | 17 |
days respectively | 17 |
comparative analysis | 17 |
malignant lymphoma | 17 |
crp levels | 17 |
acute myelogenous | 17 |
neoplastic cells | 17 |
obstructive hydrocephalus | 17 |
mechanical thrombectomy | 17 |
genetic material | 17 |
csf cultures | 17 |
primary disease | 17 |
potential biomarkers | 17 |
pediatric hsct | 17 |
mrna levels | 17 |
kg hr | 17 |
major surgery | 17 |
miltenyi biotec | 17 |
csf igg | 17 |
brentuximab vedotin | 17 |
blood counts | 17 |
japanese encephalitis | 17 |
trem variant | 17 |
placebo controlled | 17 |
free radical | 17 |
ric regimen | 17 |
rankin score | 17 |
elevated neopterin | 17 |
medical treatment | 17 |
baseline values | 17 |
pbsc collection | 17 |
patients developing | 17 |
showed higher | 17 |
day period | 17 |
cognitive function | 17 |
central line | 17 |
disc disease | 17 |
good outcomes | 17 |
log rank | 17 |
cancer progression | 17 |
early recognition | 17 |
clinical variables | 17 |
sct group | 17 |
hsct using | 17 |
clinical picture | 17 |
immune modulation | 17 |
cell response | 17 |
admission gcs | 17 |
donor lymphocytes | 17 |
microglial cells | 17 |
categorical variables | 17 |
evs secreted | 17 |
whole cohort | 17 |
therapeutic intervention | 17 |
mumps virus | 17 |
cells within | 17 |
retrospectively collected | 17 |
gradient centrifugation | 17 |
negative patients | 17 |
increased serum | 17 |
urine samples | 17 |
demographic data | 17 |
report two | 17 |
neuromyelitis optica | 17 |
antiretroviral therapy | 17 |
related death | 17 |
brain damage | 17 |
machine learning | 17 |
cell evs | 17 |
derived macrophages | 17 |
may reduce | 17 |
oxygen radicals | 17 |
novel approach | 17 |
triple negative | 17 |
highly effective | 17 |
medical school | 17 |
decreased significantly | 17 |
soluble trem | 17 |
radiation therapy | 17 |
peripheral eosinophilia | 17 |
ewing sarcoma | 17 |
patients due | 17 |
myeloid malignancies | 17 |
human blood | 17 |
health status | 17 |
analyzed data | 17 |
renal cell | 17 |
transplantation cyclophosphamide | 17 |
severe head | 17 |
cd lymphocytes | 17 |
vascular resistance | 17 |
expression patterns | 17 |
eeg patterns | 17 |
hospital course | 17 |
aml mds | 17 |
donor transplant | 16 |
important cause | 16 |
chronic renal | 16 |
significant role | 16 |
gradient ultracentrifugation | 16 |
negative control | 16 |
cell grafts | 16 |
cellular immune | 16 |
adv infection | 16 |
prospective trials | 16 |
surgical procedures | 16 |
cytometry using | 16 |
closely related | 16 |
leukemia cells | 16 |
pulmonary complications | 16 |
brain cells | 16 |
whereas patients | 16 |
neutropenic patients | 16 |
flow filtration | 16 |
previous treatment | 16 |
using two | 16 |
ejection fraction | 16 |
motif chemokine | 16 |
mortality associated | 16 |
see table | 16 |
renal insufficiency | 16 |
thiamine deficiency | 16 |
vast majority | 16 |